



Vorstandsvorsitzender: Prof. Dr. med. Stefan A. Loening

WISSENSCHAFTLICHE BEITRÄGE

2008-2015

Berliner Forschungsinstitut für Urologie

**Geschäftsführer: Prof. Dr. med. Michael Lein,
Prof. Dr. med. Carsten Stephan**

Hans-Schildbach-Stiftungsprofessur für Urogenitale Krebsforschung am MDC

Prof. Dr. med. Kai Schmidt-Ott

Die aufgeführten Beiträge sind erschienen bzw. zur Publikation angenommen/eingereicht
unter Benennung von:

Berliner Forschungsinstitut für Urologie oder
Hans-Schildbach-Stiftungsprofessur für Urogenitale Krebsforschung,
Max-Delbrueck-Centrum für Molekulare Medizin Berlin-Buch
bzw. durch Hinweis auf Förderung durch die
Stiftung Urologische Forschung.

Stand: 31.1.2016

INHALTSVERZEICHNIS

| | |
|-------------------|-----------|
| 2008 | 2 |
| 2009 | 3 |
| 2010 | 5 |
| 2011 | 7 |
| 2012 | 8 |
| 2013 | 10 |
| 2014 | 11 |
| 2015 | 13 |
| 2016 | 14 |

2008

1. **Jung K**, Klotzek S, **Stephan C**, Mannello F, **Lein M**. Impact of blood sampling on the circulating matrix metalloproteinases 1, 2, 3, 7, 8, and 9. *Clin Chem* 2008;54:772-4.
2. **Stephan C**, Kahrs A-M, Klotzek S, Reiche J, Müller C, **Lein M**, Deger S, Miller K, **Jung K**. Toward metrological traceability in the determination of prostate-specific antigen (PSA): calibrating Beckman Coulter Hybritech Access PSA assays to WHO standards compared with the traditional Hybritech standards. *Clin Chem Lab Med* 2008;46:623-9.
3. Ramankulov A, **Lein M**, Johannsen M, Schrader M, Miller K, **Jung K**. Plasma matrix metalloproteinase-7 as metastatic marker and survival predictor in patients with renal cell carcinoma. *Cancer Sci* 2008;99:1188-94.
4. **Stephan C**, **Jung K**. Editorial Comment on: Diagnostic value of free prostate-specific antigen among men with a prostate-specific antigen level of <3.0 µg per liter. *Eur Urol* 2008;54:368-9.
5. **Stephan C**, **Jung K**, **Lein M**. Editorial comment: [-2]Proenzyme prostate specific antigen for prostate cancer detection: a National Cancer Institute Early Detection Research Network validation study. L.J. Sokoll, Y. Wang, Z. Feng, J. Kagan. A.W. Partin, M.G. Sanda, I.M. Thompson, D.W. Chan. *J Urol* 2008;180:543.
6. Mannello F, **Jung K**. Blood sampling affects circulating TIMP-1 concentration, a useful biomarker in estimating liver fibrosis stages. *Hepatology* 2008;48:688-9.
7. **Jung K**. Is serum matrix metalloproteinase 9 a useful biomarker in detection of colorectal cancer? Considering pre-analytical interference that may influence diagnostic accuracy. *Brit J Canc* 2008;99:553-4.
8. Ramankulov A, **Lein M**, Johannsen M, Schrader M, Miller K, Loening SA, **Jung K**. Serum amyloid A as indicator of distant metastases but not as early tumor marker in patients with renal cell carcinoma. *Cancer Lett* 2008;269:85-92.
9. **Stephan C**, Büker N, Cammann H, Meyer H-A, **Lein M**, **Jung K**. Artificial neural network (ANN) velocity better identifies benign prostatic hyperplasia but not prostate cancer compared with PSA velocity. *BMC Urology* 2008;8:10.
10. Ludwig S, **Stephan C**, **Jung K**. Editorial comment. *J Urol* 2008;180:1312-3.
11. **Stephan C**, Cammann H, Meyer H-A, Müller C, Deger S, **Lein M**, **Jung K**. An artificial neural network for five different assay systems of prostate-specific antigen in prostate cancer diagnostics. *BJU Int* 2008;102:799-805.
12. **Jung K**, Ramankulov A, Schrader M, Miller K, **Lein M**. Circulating matrix metalloproteinase 7 - an early or metastatic marker for renal cell carcinoma? *Clin Chem* 2008;54:1927-9.

13. **Jung K.** Measurement of matrix metalloproteinases and their inhibitors in serum produces doubtful results. *J Infect Dis* 2008;198:1721-3.
14. Fritzsche FR, Riener MO, Dietel M, Moch H, **Jung K**, Kristiansen G. GOLPH2 expression in renal cell cancer. *BMC Urology* 2008;8:15.
15. Mannello F, **Jung K**, Tonti GA, Canestrari F. Heparin affects matrix metalloproteinases and tissue inhibitors of metalloproteinases circulating in peripheral blood. *Clin Biochem* 2008;41:1466-73.
16. Fritzsche FR, Weichert W, Roske A, Gekeler V, Beckers T, **Stephan C**, **Jung K**, Scholmann K, Denkert C, Dietel M, Kristiansen G. Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer. *BMC Cancer* 2008;8:381.

2009

17. **Jung K**, **Lein M.** By mistakes we learn: determination of matrix metalloproteinase-8 and tissue inhibitor of matrix metalloproteinase-1 in serum yields doubtful results. *J Clin Periodontol* 2009;36:34-5.
18. **Stephan C**, Kahrs A-M, Cammann H, **Lein M**, Schrader M, Deger S, **Jung K.** A [-2]proPSA-based artificial neural network significantly improves differentiation between prostate cancer and benign prostatic diseases. *Prostate* 2009;69:198-207.
19. Meyer HA, Tölle A, Jung M, Fritzsche FR, Haendler B, Kristiansen I, Gaspert A, Johannsen M, **Jung K**, Kristiansen G. Identification of Stanniocalcin 2 as prognostic marker in renal cell carcinoma. *Eur Urol* 2009;55:669-78.
20. Erbersdobler A, Isbarn H, **Steiner I**, Schlomm T, Chun F, Mirlacher M, Sauter G. Predictive value of prostate-specific antigen expression in prostate cancer: a tissue microarray study. *Urology* 2009;74:1169-73.
21. **Lein M**, Miller K, Wirth M, Weißbach L, May C, Schmidt K, Haus U, Schrader M, **Jung K.** Bone turnover markers as predictive tools for skeletal complications in men with metastatic prostate cancer treated with zoledronic acid. *Prostate* 2009;69:624-32.
22. Abramjuk C, Bueschges M, Schnorr J, **Jung K**, Staack A, **Lein M.** Divergent effects of taurolidine as potential anti-neoplastic agent: inhibition of bladder carcinoma cells in vitro and promotion of bladder tumor in vivo. *Oncol Rep* 2009;22:409-14.
23. **Stephan C**, Rittenhouse HG, Cammann H, **Lein M**, Schrader M, Deger S, Miller K, **Jung K.** New markers and multivariate models for prostate cancer detection. *Anticancer Res* 2009;29:2589-600.
24. Toelle A, Jung M, **Lein M**, Johannsen M, Miller K, Moch H, **Jung K**, Kristiansen G. Brain-type and liver-type fatty acid-binding proteins: new tumor markers for renal cancer? *BMC Cancer* 2009;9:248.

25. **Stephan C**, Bangma C, Vignati G, Bartsch G, **Lein M**, **Jung K**, Philippe M, Semjonow A, Catalona WJ. 20-25% lower concentrations of total and free prostate specific antigen (PSA) after calibration of PSA assays to the WHO reference materials – analysis of 1098 patients in four centers. *Int J Biol Markers* 2009;24:65-9.
26. **Stephan C**, Cammann H, Rittenhouse H, **Lein M**, Jentzmik F, Schrader M, Deger S, Miller K, **Jung K**. Neue Biomarker und Anwendung multivariater Modelle zur Detektion des Prostatakarzinoms. *Aktuel Urol* 2009;40:221-30.
27. Kempkensteffen C, Fritzsche FR, Johannsen M, Weikert S, Hinz S, Dietel M, Riener M-O, Moch H, **Jung K**, Krause H, Miller K, Kristiansen G. Down-regulation of the pro-apoptotic XIAP associated factor-1 (XAF1) during progression of clear-cell renal cancer. *BMC Cancer* 2009;9:276.
28. **Schaefer A**, Jung M, Kristiansen G, **Lein M**, Schrader M, Miller K, Erbersdobler A, **Stephan C**, **Jung K**. MicroRNAs in der Uro-Onkologie - Neue Hoffnungen für die Diagnostik und Therapie von Tumoren? *Urologe* 2009;48:877-85.
29. Meyer H-A, Hollenbach B, **Stephan C**, Endermann T, Morgenthaler NG, Cammann H, Köhrle J, **Jung K**, Schomburg L. Reduced serum selenoprotein P concentrations in German prostate cancer patients. *Cancer Epidemiol Biomark Prevent* 2009;18:2386-90.
30. **Stephan C**, Cammann H, Deger S, Schrader M, Meyer HA, Miller K, **Lein M**, **Jung K**. Benign prostatic hyperplasia-associated free prostate-specific antigen improves detection of prostate cancer in an artificial neural network. *Urology* 2009;74:873-7.
31. **Jung K**, Mannello F, **Lein M**. Translating molecular medicine into clinical tools: doomed to fail by neglecting basic preanalytical principles. *J Translat Med* 2009;7:87.
32. **Stephan C**, Köpke, T., Semjonow A, **Lein M**, Deger S, Schrader M, Miller K, **Jung K**. Discordant total and free prostate-specific antigen (PSA) assays: does calibration with WHO reference materials diminish the problem? *Clin Chem Lab Med* 2009;47:1325-31.
33. **Jung K**. Consideration of preanalytical impact of blood sampling on measurement of matrix metalloproteinases and their inhibitors as precondition to evaluate their relationship to clinical data. *Mult Scler* 2009;15:1372-3.
34. Ferrer R, Lobo G, Gambo N, Rodrigues J, Abramjuk C, **Jung K**, **Lein M**, Charris JE. Synthesis of 7-chloroquinolinyl-4-aminophenylchalcones: potential antimalarial and anticancer agents. *Sci Pharm* 2009;77:725-41.
35. Jung M, Mollenkopf H-J, Grimm C, Wagner I, Albrecht M, Waller T, Pilarsky C, Johannsen M, **Stephan C**, Lehrach H, Nietfeld W, Rudel T, **Jung K**, Kristiansen G. MicroRNA profiling of clear cell renal cell cancer identifies a robust signature to define renal malignancy. *J Cell Mol Med* 2009;13:3918-28.

2010

36. **Nitzsche B**, Gloesenkamp C, Schrader M, Ocker M, Preissner R, Lein M, Zakrzewicz A, Hoffmann B, Hopfner M. Novel compounds with antiangiogenic and antiproliferative potency for growth control of testicular germ cell tumours. *Brit J Canc* 2010;103:18-28.
37. **Schaefer A**, Jung M, Kristiansen G, **Lein M**, Schrader M, Miller K, **Stephan C**, **Jung K**. MicroRNAs and cancer: current state and future perspectives in urologic oncology. *Urol Oncol* 2010;28:4-13.
38. **Schaefer A**, Jung M, Mollenkopf H-J, Wagner I, **Stephan C**, Jentzmik F, Miller K, **Lein M**, Kristiansen G, **Jung K**. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. *Int J Cancer* 2010;126:1166-76.
39. **Stephan C**, Cammann H, Bender M, Miller K, **Lein M**, **Jung K**, Meyer H-A. Internal validation of an artificial neural network for prostate biopsy outcome. *Int J Urol* 2010;17:62-8.
40. Diamandis EP, Walsh PC, **Jung K**, Catalona WJ, Fleshner N. Prostate cancer screening with prostate-specific antigen testing: more answers or more confusion? Interview with PC Wals, K Jung, WJ Catalona, N Fleshner. *Clin Chem* 2010;56:345-51.
41. **Schaefer A**, **Jung K**. Re: MicroRNA regulation of oncolytic herpes simplex virus-1 for selective killing of prostate cancer cells. *Eur Urol* 2010;57:919.
42. Fritzsche FR, **Stephan C**, Gerhardt J, **Lein M**, Hofmann I, **Jung K**, Dietel M, Kristiansen G. Diagnostic and prognostic value of T-cell receptor gamma alternative reading frame protein (TARP) expression in prostate cancer. *Histol Histopathol* 2010;25:733-9.
43. **Schaefer A**, **Stephan C**, Busch J, Yousef GM, **Jung K**. Diagnostic, prognostic, and therapeutic implications of miRNAs in urologic tumors. *Nat Rev Urol* 2010;7:286-97.
44. **Jung K**, Wu C-W. Methodological weakness in using correlation coefficients for assessing the interchangeability of analyte data between samples collected under different sampling conditions - the example of matrix metalloproteinase 9 determined in serum and plasma samples. *Clin Chem Lab Med* 2010;48:733-6.
45. Tischler V, Fritzsche FR, Gerhardt J, Jäger C, **Stephan C**, **Jung K**, Dietel M, Moch H, Kristiansen G. Comparison of the diagnostic value of fatty acid synthase (FASN) to alpha-methylacyl-CoA racemase (AMACR) as prostate cancer tissue marker . *Histopathology* 2010;56:811-5.
46. Tölle A, Abdallah Z, **Jung K**, Bäuml H. Measurement conditions for flow cytometry analyses of cell lines from urologic carcinomas. *J Fluoresc* 2010;20:779-86.

47. Jung M, **Schaefer A**, **Steiner I**, Kempkensteffen C, **Stephan C**, Erbersdobler A, **Jung K**. Robust microRNA stability in degraded RNA preparations from human tissue and cell samples. *Clin Chem* 2010;56:998-1006.
48. Jentzmik F, **Stephan C**, Miller K, Schrader M, Erbersdobler A, Kristiansen G, **Lein M**, **Jung K**. Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours. *Eur Urol* 2010;58:12-8.
49. **Stephan C**, Jentzmik F, **Jung K**. Re: Jack A. Schalken. Is urinary sarcosine useful to identify patients with significant prostate cancer? The trials and tribulations of biomarker development. *Eur Urol* 2010;58:20-21. *Eur Urol* 2010;58:20-1.
50. Tischler V, Fritzsche FR, Wild PJ, **Stephan C**, Seifert H-H, Riener MO, Hermanns T, Mortzawi A, Gerhardt J, Schraml P, **Jung K**, Moch H, Soltermann A, Kristiansen G. Periostin is up-regulated in high grade and high stage prostate cancer. *BMC Cancer* 2010;10:273.
51. Jentzmik F, **Stephan C**, **Jung K**. Reply to Arun Sreekumar, Laila M. Poisson, Thekkelnaycke M. Rajendrian, et al.'s Letter to the Editor re: Florian Jentzmik, Carsten Stephan, Kurt Miller, et al. Sarcosine in urine after digital examination fails as a marker in prostate cancer detection and identification of aggressive tumors. *Eur Urol* 2010;58:12-8. *Eur Urol* 2010;58:e31-e32.
52. Jentzmik F, **Stephan C**, **Jung K**. Reply to Amitha K Hewavitharana's Letter to the Editor re: Florian Jentzmik, Carsten Stephan, Kurt Miller, et al. Sarcosine in urine after digital examination fails as a marker in prostate cancer detection and identification of aggressive tumors. *Eur Urol* 2010;58:12-8. *Eur Urol* 2010;58:e41-e42.
53. Erbersdobler A, Isbarn H, Dix K, **Steiner I**, Schlomm T, Mirlacher M, Sauter G, Haese A. Prognostic value of microvessel density in prostate cancer: a tissue microarray study. *World J Urol* 2010;28:687-92.
54. **Jung K**, Fleischhacker M, Rabien A. Cell-free DNA in the blood as a solid tumor biomarker - a critical appraisal of the literature. *Clin Chim Acta* 2010;411:1611-24.
55. Rabien A, Fritzsche F, Jung M, Diamandis EP, Miller K, **Jung K**, Kristiansen G, **Stephan C**. KLK15 is a prognostic marker for progression-free survival in patients with radical prostatectomy. *Int J Cancer* 2010;127:2386-94.
56. **Steiner I**, **Jung K**, Schatz P, Horns T, Wittschieber D, **Lein M**, Dietel M, Erbersdobler A. Gene promoter methylation and its potential relevance in early prostate cancer diagnosis. *Pathobiology* 2010;77:260-6.
57. **Schaefer A**, Jung M, **Stephan C**, Miller K, **Lein M**, Kristiansen G, Erbersdobler A, **Jung K**. Suitable reference genes for relative quantification of miRNA expression in prostate cancer. *Exp Mol Med* 2010;42:749-58.

2011

58. Jentzmik F, **Stephan C, Lein M**, Miller K, Kamlage B, Bethan B, Kristiansen G, **Jung K**. Sarcosine in prostate cancer tissue is not a differential metabolite for prostate cancer aggressiveness and biochemical progression. *J Urol* 2011;185:706-11.
59. Hohberg M, Knöchel J, Hoffmann CJ, Chlench S, Wunderlich W, Alter A, Maroski J, Vorderwülbecke BJ, Silva-Azevedo LD, Knudsen R, Lehmann R, Fiedorowicz K, Bongrazio M, **Nitzsche B**, Höpfner M, Styp-Rekowska B, Pries AR, Zakrzewicz A. Expression of ADAMTS1 in endothelial cells is induced by shear stress and suppressed in sprouting capillaries. *J Cell Physiol* 2011;266:350-61.
60. White NM, Fatoohi E, Metias M, **Jung K, Stephan C**, Yousef GM. Metastamirs: a stepping stone towards improved cancer management. *Nat Rev Clin Oncol* 2011;8:75-84.
61. **Rodrigues J**, Abramjuk C, Vasquez L, Gamboa N, Dominguez J, **Nitzsche B**, Höpfner M, Georgieva R, Bäuml H, **Stephan C, Jung K, Lein M**, Rabien A. New 4-maleamic acid and 4-maleamide peptidyl chalcones as potential multitarget drugs for human prostate cancer. *Pharm Res* 2011;28:907-19.
62. **Jung K**, Miller K, Wirth M, Albrecht M, **Lein M**. Bone turnover markers as predictors of mortality risk of prostate cancer patients with bone metastases following treatment with zoledronic acid. *Eur Urol* 2011;59:604-12.
63. Toelle A, Krause H, Miller K, **Jung K, Stephan C**. Importance of brain-type fatty acid binding protein for cell-biological processes in human renal carcinoma cells. *Oncol Rep* 2011;25:1307-12.
64. Wittschieber D, Stenzinger A, Klauschen F, **Stephan C, Jung K**, Ebersdobler A, Rabien A. Decreased RECK and increased EMMPRIN expression in urothelial carcinoma of the bladder are associated with tumor aggressiveness. *Pathobiology* 2011;78:123-31.
65. Gerhardt J, Steinbrecht C, Büchi O, Behnke S, Bohnert A, Fritzsche F, Liewen H, Stenner F, Wild PJ, Müntener M, Dietel M, **Jung K, Stephan C**, Kristiansen G. The androgen-regulated calcium-activated nucleotidase 1 (CANT1) is commonly overexpressed in prostate cancer and is tumor-biologically relevant in vitro. *Am J Pathol* 2011;178:1847-60.
66. **Stephan C**, Siemssen K, Cammann H, Friedersdorf F, Deger S, Schrader M, Miller K, **Lein M, Jung K**, Meyer H-A. Between-method differences in prostate-specific antigen assays affect prostate cancer risk prediction by nomograms. *Clin Chem* 2011;57:995-1004.
67. **Fendler A, Stephan C**, Yousef GM, **Jung K**. MiRNAs as regulators of signal transduction in urological tumors. *Clin Chem* 2011;57:954-68.
68. Toelle A, Suhail S, Jung M, **Jung K, Stephan C**. Fatty acid binding proteins (FABPs) in prostate, bladder, and kidney cancer cell lines and the use of IL-

FABP as survival predictor in patients with renal cell carcinoma. *BMC Cancer* 2011;11:302.

69. **Wotschofsky Z**, Meyer H-A, Jung M, **Fendler A**, Wagner I, **Stephan C**, Busch J, Erbersdobler A, Disch AC, Mollenkopf H-J, **Jung K**. Reference genes for the relative quantification of microRNAs in renal cell carcinomas and their metastases. *Analyt Biochem* 2011;417:233-41.
70. **Stephan C**, Miller K, **Jung K**. Is there an optimal prostate-specific antigen threshold for prostate biopsy? *Expert Rev Anticancer Ther* 2011;11:1215-21.
71. **Fendler A**, Jung M, **Stephan C**, Honey RJ, Stewart RJ, Pace KT, Erbersdobler A, Samaan S, **Jung K**, Yousef GM. MiRNAs can predict prostate cancer biochemical relapse and are involved in tumor progression. *Int J Oncol* 2011;39:1183-92.
72. Cammann H, **Jung K**, Meyer H-A, **Stephan C**. Avoiding pitfalls in applying prediction models, as illustrated by the example of prostate cancer diagnosis. *Clin Chem* 2011;57:1490-8.
73. **Jung K**. Preanalytical interferences compromise the clinical validity of matrix metalloproteinase 1 as marker of colorectal cancer. *Ann Surg Oncol* 2011;18, Suppl 3:S231-S232.

2012

74. **Steiner I**, **Jung K**, Miller K, **Stephan C**, Erbersdobler A. Expression of endothelial factors in prostate cancer: a possible role of caveolin-1 for tumor progression. *Oncol Rep* 2012;27:389-95.
75. Gloesenkamp C, **Nitzsche B**, Ocker M, Di Fazio P, Quint K, Hoffmann B, Scherübl H, Höpfner M. AKT inhibition by triciribine alone or as combination therapy for growth control of gastroenteropancreatic neuroendocrine tumors. *Int J Oncol* 2012;40:876-88.
76. **Jung K**, **Stephan C**, **Lein M**. Assay-dependent abnormalities in measurements of prostate-specific antigen in serum: an occasional occurrence, but of clinical significance. *Clin Chem Lab Med* 2012;50:585-6.
77. Patron JP, **Fendler A**, Jung U, Mueller H, Arntzen MO, **Stephan C**, Thiede B, Mollenkopf H-J, **Jung K**, Kaufmann SHE, Schreiber J. MiR-133b targets antiapoptotic genes and enhances death receptor-induced apoptosis. *PLoS One* 2012;7:e35345.
78. **Liep J**, Rabien A, **Jung K**. Feedback networks between microRNAs and epigenetic modifications in urological tumors. *Epigenetics* 2012;7:315-25.
79. White NM, Youssef YM, **Fendler A**, **Stephan C**, **Jung K**, Yousef GM. The microRNA-kallikrein axis of interaction: a new dimension in the pathogenesis of prostate cancer. *Biol Chem* 2012;393:379-89.

80. Gloesenkamp C, **Nitzsche B**, Lim AR, Normant E, Vosburgh E, Schrader M, Ocker M, Scherübl H, Höpfner M. Heat shock protein 90 is a promising target for effective growth inhibition of gastrointestinal neuroendocrine tumors. *Int J Oncol* 2012;40:1659-67.
81. Rabien A, Erguen B, Erbersdobler A, **Jung K, Stephan C**. RECK overexpression decreases invasive potential in prostate cancer cells. *Prostate* 2012;72:948-54.
82. **Ratert N**, Meyer H-A, Jung M, Mollenkopf H-J, Wagner I, Miller K, Kilic E, Erbersdobler A, Weikert S, **Jung K**. Reference miRNAs for miRNAome analysis of urothelial carcinomas. *PLoS One* 2012;7:e39309.
83. **Rodrigues JR**, Charris J, Ferrer R, Gamboa N, Angel J, Nitzsche B, Hoepfner M, **Lein M, Jung K, Abramjuk C**. Effect of quinolinyl acrylate derivatives on prostate cancer *in vitro* and *in vivo*. *Invest New Drug* 2012;30:1426-33.
84. Ecke TH, Bartel P, Hallmann S, Koch S, Ruttloff J, Cammann H, **Lein M, Schrader M, Miller K, Stephan C**. Outcome prediction for prostate cancer detection rate with artificial neural network (ANN) in daily routine. *Urol Oncol* 2012;30:139-44.
85. Ecke TH, Hallmann S, Koch S, Ruttloff J, Cammann H, Gerullis H, Miller K, **Stephan C**. External validation of an artificial neural network and two nomograms for prostate cancer detection. *ISRN Urol* 2012;2012:643181.
86. Meyer HA, Endermann T, **Stephan C**, Stoedter M, Behrends T, Wolff I, **Jung K**, Schomburg L. Selenoprotein P status correlates to cancer-specific mortality in renal cancer patients. *PLoS One* 2012;7:e46644.
87. Busch J, Hamborg K, Meyer H-A, Buckendahl A, Magheli A, Lein M, **Jung K, Miller K, Stephan C**. Value of PSA density and percent free PSA for prostate cancer prognosis. *J Urol* 2012;188:2165-70.
88. Busch J, **Stephan C**, Herold A, Erber B, Kempkensteffen C, Hinz S, Lein M, Weikert S, Miller K, Magheli A. Long-term oncological and continence outcomes after laparoscopic radical prostatectomy: a single-centre experience. *BJU Int* 2012;110:E985-E990.
89. **Wotschofsky Z, Liep J**, Meyer H-A, Jung M, Wagner I, Disch AC, Schaser KD, Melcher I, Kilic E, Busch J, Weikert S, Miller K, Erbersdobler A, Mollenkopf H-J, **Jung K**. Identification of metastamirs as metastasis-associated microRNAs in clear cell renal cell carcinomas. *Int J Biol Sci* 2012;8:1363-74.
90. **Nitzsche B**, Gloesenkamp C, Schrader M, Hoffmann B, Zengerling F, Balabanov S, Honecker F, Hopfner M. Anti-tumour activity of two novel compounds in cisplatin-resistant testicular germ cell cancer. *Br J Cancer* 2012;107:1853-63.

2013

91. Busch J, **Stephan C**, Klutzny A, Hinz S, Kempkensteffen C, Kilic E, **Lein M**, Weikert S, Miller K, Magheli A. Impact of positive surgical margins on oncological outcome following laparoscopic radical prostatectomy (LRP): long-term results. *World J Urol* 2013;31:395-401.
92. **Wotschofsky Z**, Busch J, Jung M, Kempkensteffen C, Weikert S, Schaser KD, Melcher I, Kilic E, Miller K, Kristiansen G, Erbersdobler A, **Jung K**. Diagnostic and prognostic potential of differentially expressed miRNAs between metastatic and non-metastatic renal cell carcinoma at the time of nephrectomy. *Clin Chim Acta* 2013;416:5-10.
93. **Jung K**. Editorial comment: "A review of expression profiling of circulating microRNAs in men with prostate cancer". *BJU Int* 2013;111:3-4.
94. **Stephan C, Jung K**. Editorial "TMPRSS2-ERG fusion transcripts in matched urine and needle rinse material after biopsy for the detection of prostate cancer: really a step forward? *Clin Chem* 2013;59:9-10.
95. **Stephan C, Jung K**, Semjonow A, Schulze-Forster K, Cammann H, Hu X, Meyer H-A, Bögemann M, Miller K, Friedersdorff F. Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion with the serum [-2]prostate-specific antigen-based prostate health index for detection of prostate cancer. *Clin Chem* 2013;59:280-8.
96. **Stephan C**, Vincendeau S, Houlgatte A, Cammann H, **Jung K**, Semjonow A. Multicenter evaluation of [-2]prostate-specific antigen and the prostate health index for detecting prostate cancer. *Clin Chem* 2013;59:306-14.
97. Perner S, Rupp NJ, Braun M, Rubin MA, Moch H, Dietel M, Wernert N, **Jung K, Stephan C**, Kristiansen G. Loss of SLC45A3 protein (prostein) expression in prostate cancer is associated with SLC45A3-ERG gene rearrangement and an unfavorable clinical course. *Int J Cancer* 2013;132:807-12.
98. **Rodrigues JR**, Charris J, Camacho J, Barazarte A, Gamboa N, **Nitzsche B**, Hopfner M, **Lein M, Jung K**, Abramjuk C. N¹-formyl-2-(5-nitrothiophen-2-yl)benzothiazole-6-carbohydrazide as potential antitumor agent for prostate cancer in experimental studies. *J Pharm Pharmacol* 2013;65:411-22.
99. Hu X, Cammann H, Meyer H-A, Miller K, **Jung K, Stephan C**. Artificial neural networks and prostate cancer - tools for diagnosis and management. *Nat Rev Urol* 2013;10:174-82.
100. **Fendler A, Jung K**. microRNAs as new diagnostic and prognostic biomarkers in urological tumors. *Crit Rev Oncog* 2013;18:289-302.
101. **Gummlich L, Rabien A, Jung K**, Dubiel W. Deregulation of the COP9 signalosome-cullin-RING ubiquitin-ligase pathway: mechanisms and roles in urological cancers. *Int J Biochem Cell Biol* 2013;45:1327-37.

102. Hecker N, **Stephan C**, Mollenkopf H-J, **Jung K**, Preissner R, Meyer H-A. A new algorithm for the integrated analysis of miRNA-mRNA interactions based on individual classification reveals insights into bladder cancer. *PLoS One* 2013;8:e64543.
103. **Jung K**. Pitfalls in the determination of circulating matrix metalloproteinases and their inhibitors by disregarding fundamental laboratory principles. *Am Heart J* 2013;165:e31.
104. Sailer V, **Stephan C**, Wernert N, Perner S, **Jung K**, Dietel M, Kristiansen G. Comparison of p40 (Δ Np63) and p63 expression in prostate tissues - which one is the superior diagnostic marker for basal cells? *Histopathology* 2013;63:50-6.
105. **Ratert N**, Meyer H-A, Jung M, Lioudmer P, Mollenkopf H-J, Wagner I, Miller K, Kilic E, Erbersdobler A, Weikert S, **Jung K**. MicroRNA profiling identifies candidate miRNAs for bladder cancer diagnosis and clinical outcome. *J Mol Diagn* 2013;15:695-705.
106. Tölle A, Jung M, Rabenhorst S, Kilic E, **Jung K**, Weikert S. Identification of microRNAs in blood and urine as tumour markers for the detection urinary bladder cancer. *Oncol Rep* 2013;30:1949-56.
107. **Jung K**, **Stephan C**. Thiosulfate in urine: new hope or new failure of a biomarker for prostate cancer? *Clin Chem Lab Med* 2013;51:1695-7.
108. **Jung K**, Reszka R, Kamlage B, Bethan B, **Lein M**, **Stephan C**, Kristiansen G. Tissue metabolite profiling identifies differentiating and prognostic biomarkers for prostate carcinoma. *Int J Cancer* 2013;133:2914-24.
109. Lichner Z, **Fendler A**, Saleh C, Nasser AN, Boles D, Al-Haddad S, Kupchak P, Dharsee M, Nuin PS, Evans KR, **Jung K**, **Stephan C**, Fleshner NE, Yousef GM. MicroRNA signature helps distinguish early from late biochemical failure in prostate cancer. *Clin Chem* 2013;59:1595-604.
110. **Rabien A**, **Stephan C**, Kilic E, Weichert W, Kristiansen G, Miller K, **Jung K**, Erbersdobler A. Renal cell carcinoma: RECK discriminates tumor subtypes, while Emmprin indicates prognosis. *J Translat Med* 2013;11:258.
111. **Fendler A**, Jung M, **Stephan C**, Erbersdobler A, **Jung K**, Yousef GM. The antiapoptotic function of miR-96 in prostate cancer by inhibition of FOXO1. *PLoS One* 2013;8:e80807.

2014

112. **Stephan C**, Rittenhouse H, Hu X, **Jung K**. Prostate-specific antigen (PSA) screening and new biomarkers for prostate cancer (PCa). *eJIFCC* 2014;25:55-78.
113. **Stephan C**, Ralla B, **Jung K**. Prostate-specific antigen and other serum and urine markers in prostate cancer. *BBA-Rev Cancer* 2014;1846:99-112.

114. Friedersdorff F, Manus P, Miller K, **Lein M, Jung K, Stephan C**. Serum testosterone improves the accuracy of prostate health index for the detection of prostate cancer. *Clin Biochem* 2014;47:916-20.
115. Maxeiner A, Fischer T, **Stephan C**, Cash H, Slowinski T, Kilic E, Durmus T. Die Echtzeit-MRT/US-Fusionsbiopsie verbessert die Detektionsrate des Prostatakarzinoms nach mehrfach negativen Vorbiopsien. *Akt Urol* 2014;45:197-203.
116. Zimpfer A, Maruschke M, Rehn S, Kundt G, Litzenberger A, Dammert F, Zettl H, **Stephan C**, Hakenberg OW, Erbersdobler A. Prognostic and diagnostic implications of epithelial cell adhesion/activating molecule (EpCAM) expression in renal tumours: a retrospective clinicopathological study of 948 cases using tissue microarrays. *BJU Int* 2014;114:296-302.
117. Dietrich D, Meller S, Uhl B, Ralla B, **Stephan C, Jung K**, Ellinger J, Kristiansen G. Nucleic acid-based tissue biomarkers of urologic malignancies. *Crit Rev Clin Lab Sci* 2014;51:173-99.
118. Ralla B, **Stephan C**, Meller S, Dietrich D, Kristiansen G, **Jung K**. Nucleic acid-based biomarkers in body fluids of patients with urologic malignancies. *Crit Rev Clin Lab Sci* 2014;51:200-31.
119. Tölle A, **Ratert N, Jung K**. miRNA panels as biomarkers for bladder cancer. *Biomark Med* 2014;8:733-46.
120. Stein J, Majores M, Rohde M, Lim S, Schneider S, Krappe E, Ellinger J, Dietel M, **Stephan C, Jung K**, Perner S, Kristiansen G, Kirfel J. KDM5C is overexpressed in prostate cancer and is a prognostic marker for PSA-relapse following radical prostatectomy. *Am J Pathol* 2014;184:2430-7.
121. **Jung K, Lein M**. Bone turnover markers in serum and urine as diagnostic, prognostic and monitoring biomarkers of bone metastasis. *BBA-Rev Cancer* 2014;1846:425-38.
122. Meller S, Bicker A, Montani M, Ikenberg K, Rostamzahdeh B, Wild P, Dietrich D, Sulser T, Moch H, Gorr TA, **Stephan C, Jung K**, Hankeln T, Kristiansen G. Myoglobin expression in prostate cancer is correlated to androgen receptor expression and markers of tumor hypoxia. *Virchows Arch* 2014;465:419-27.
123. Wangerin H, Kristiansen G, Schlomm T, **Stephan C**, Gunia S, Zimpfer A, Weichert W, Sauter G, Erbersdobler A. CD57 expression in incidental, clinically manifest, and metastatic carcinoma of the prostate. *Biomed Res Int* 2014;2014:356427.
124. Hu X, Cammann H, Meyer H-A, **Jung K**, Lu H, Leva N, Magheli A, **Stephan C**, Busch J. Risk prediction models for biochemical recurrence after radical prostatectomy using PSA and Gleason Score. *Asian J Androl* 2014;16:897-901.

2015

125. Maxeiner A, **Stephan C**, Durmus T, Slowinski T, Cash H, Fischer T. Added value of multiparametric ultrasonography in magnetic resonance imaging and ultrasonography fusion-guided biopsy of the prostate in patients with suspicion for prostate cancer. *Urology* 2015;86:108-14.
126. Aue A, Hinze C, Walentin K, Ruffert J, **Yurtdas Y**, Werth M, Chen W, **Rabien A**, Kilic E, Schulzke JD, Schumann M, **Schmidt-Ott KM**. A Grainyhead-Like 2/Ovo-Like 2 pathway regulates renal epithelial barrier function and lumen expansion. *J Am Soc Nephrol* 2015;26:2704-15.
127. Walentin K, Hinze C, Werth M, Haase N, Varma S, Morell R, Aue A, Potschke E, Warburton D, Qiu A, Barasch J, Purfurst B, Dieterich C, Popova E, Bader M, Dechend R, Staff AC, **Yurtdas ZY**, Kilic E, **Schmidt-Ott KM**. A Grhl2-dependent gene network controls trophoblast branching morphogenesis. *Development* 2015;142:1125-36.
128. Ecke TH, Arndt C, **Stephan C**, Hallmann S, Lux O, Otto T, Ruttloff J, Gerullis H. Preliminary results of a multicentre study of the UBC rapid test for detection of urinary bladder cancer. *Anticancer Res* 2015;35:2651-5.
129. **Stephan C**, Wilkosz J, Rozanski W, Ecke T, **Lein M**, Brys M, Krzeslak A, Chwatko G, **Jung K**. Urinary thiosulfate as failed prostate cancer biomarker - an exemplary multicenter re-evaluation study. *Clin Chem Lab Med* 2015;53:477-83.
130. Lobo G, **Rodrigues J**, Gamboa N, Capparelli M, Martinez-Cuevas J, **Lein M**, **Jung K**, Charris J. Synthesis, crystal structure and effect of indeno[1,2-b]indole derivatives on prostate cancer in vitro. Potential effect against MMP-9. *Eur J Med Chem* 2015;96:481-95.
131. **Stephan C**, Ralla B, Miller K, **Jung K**. Neue Marker im Serum und im Urin zur Detektion des Prostatakarzinoms. *Aktuel Urol* 2015;46:129-43.
132. Adaramoye, O., Erguen B, Oyebode O, Nitzsche B, Höpfner M, **Jung K**, **Rabien A**. Antioxidant, antiangiogenic and antiproliferative activities of root methanol extract of *Calliandra portoricensis* in human prostate cancer cells. *J Integr Med* 2015;13:185-93.
133. Busch J, Ralla B, Jung M, **Wotschofsky Z**, **Trujillo-Arribas E**, Schwabe P, Kilic E, **Fendler A**, **Jung K**. Piwi-interacting RNAs as novel prognostic markers in clear cell renal cell carcinomas. *J Exp Clin Cancer Res* 2015;34:61.
134. **Stephan C**, Jung M, Rabenhorst S, Kilic E, **Jung K**. Urinary miR-183 and miR-205 do not surpass PCA3 in urine as predictive markers for prostate biopsy outcome despite their highly dysregulated expression in prostate cancer tissue. *Clin Chem Lab Med* 2015;53:1109-18.
135. Sailer V, Eberhard HL, **Stephan C**, Wernert N, Perner S, **Jung K**, Dietel M, Bubendorf L, Kristiansen G. Glutathione S-transferase-pi protein expression in

prostate cancer - not always a useful diagnostic tool. *Histopathology* 2015;67:577-9.

- 136. Stephan C, Cammann H, Jung K.** Re: Scott A. Tomlins, John R. Day, Robert J. Lonigro, et al. Urine TMPRSS2:ERG Plus PCA3 for individualized prostate cancer risk assessment. *Eur Urol* 2015;68:e106-e107.
- 137. Stephan C, Jung K, Ralla B.** Current biomarkers for diagnosing of prostate cancer. *Future Oncol* 2015;11:2743-55.
- 138.** Lichner Z, Ding Q, Samaan S, Saleh C, Nasser A, Al-Haddad S, Samuel JN, Fleshner NE, **Stephan C, Jung K, Yousef GM.** miRNAs dysregulated in association with Gleason grade regulate extracellular matrix, cytoskeleton and androgen receptor pathways. *J Pathol* 2015;237:226-37.
- 139.** Goltz D, Montani M, Braun M, Perner S, Wernert N, **Jung K, Dietel M, Stephan C, Kristiansen G.** Prognostic relevance of proliferation markers (Ki-67, PHH3) within the cross-relation of ERG-translocation and androgen receptor expression in prostate cancer. *Pathology* 2015;47:629-36.

2016

- 140.** Boegemann M, **Stephan C, Cammann H, Vincendeau S, Houlgatte A, Jung K, Blanchet JS, Semjonow A.** The percentage of prostate-specific antigen (PSA) isoform [-2]proPSA and the Prostate Health Index improve the diagnostic accuracy for clinically relevant prostate cancer at initial and repeat biopsy compared with total PSA and percentage free PSA in men aged =65 years. *BJU Int* 2016;117:72-9.
- 141.** Lu H, Busch J, Jung M, Rabenhorst S, Ralla B, Kilic E, Mergemeier S, Budach N, Fendler A, **Jung K.** Diagnostic and prognostic potential of circulating cell-free genomic and mitochondrial DNA fragments in clear cell renal cell carcinoma patients. *Clin Chim Acta* 2016;452:109-19.
- 142.** Gevensleben H, Dietrich D, Golletz C, Steiner S, Jung M, Thiesler T, Majores M, Stein J, Uhl B, Mueller S, Ellinger J, **Stephan C, Jung K, Brossart P, Kristiansen G.** The immune checkpoint regulator PD-L1 is highly expressed in aggressive primary prostate cancer. *Clin Cancer Res* 2016; Epub ahead of print, November 16, 2015; doi:10.1158/1078-0432.CCR-15-2042.
- 143.** Berg KD, Soldini D, Jung M, Dietrich D, **Stephan C, Jung K, Dietel M, Vainer b, Kristiansen G.** TRPM4 protein expression in prostate cancer: a novel tissue biomarker associated with risk of biochemical recurrence following radical prostatectomy. *Virchows Arch* 2016; Epub ahead of print, November 21, 2015; doi:10.1007/s00428-015-1880-y.
- 144.** Meller S, Meyer HA, Bethan B, Dietrich D, Gonzalez Maldonado S, Lein M, Montani M, Reszka R, Schatz P, Peter E, **Stephan C, Jung K, Kamlage B, Kristiansen G.** Integration of tissue metabolomics, transcriptomics and immunohistochemistry reveals ERG- and Gleason score- specific metabolomic

alterations in prostate cancer. *Oncotarget* 2016; Epub ahead of print, November 23, 2015; doi:10.18632/oncotarget.6370.

145. **Stephan C, Jung K.** The way of prostate cancer diagnostics. Editorial to "Comparative analysis of prostate cancer specific biomarkers PCA3 and ERG in whole urine, urinary sediment and exosomes" by Hendriks RJ, Dijkstra S, Jannink SA, Steffens MG, Van Oort IM, Mulders PFA, Schalken JA. *Clin Chem Lab Med* 2016; Epub ahead of print; January 7, 2016; doi:10.1515/cclm-2015-1114.
146. Sugawara T, Lejeune P, Köhr S, Neuhaus R, Faus H, Gelato KA, Busemann M, Cleve A, Lücking U, von Nussbaum F, Brands M, Mumberg D, **Jung K, Stephan C**, Haendler B. BAY 1024767 blocks androgen receptor mutants found in castration-resistant prostate cancer patients. *Oncotarget* 2016; Epub ahead of print, January 9, 2016; doi: 10.18632/oncotarget.6864.
147. Walentin K, Hinze C, **Schmidt-Ott KM.** The basal chorionic trophoblast cell layer: An emerging coordinator of placenta development. *Bioessays* 2016; Epub ahead of print, January 18, 2016; doi:10.1002/bies.201500087.
148. Marko L, Vigolo E, Hinze C, Park JK, Roel G, Balogh A, Choi M, Wubken A, Cording J, Blasig IE, Luft FC, Scheidereit C, **Schmidt-Ott KM**, Schmidt-Ullrich R, Muller DN. Tubular Epithelial NF-kappaB Activity Regulates Ischemic AKI. *J Am Soc Nephrol* 2016; Epub ahead of print, January 28, 2016; doi:10.1681/ASN.2015070748.
149. **Wotschofsky Z, Gummlich L, Liep J, Stephan C**, Kilic E, **Jung K**, Billaud JN, Meyer HA. Integrated microRNA and mRNA signature associated with the transition from the locally confined to the metastasized clear cell renal cell carcinoma exemplified by miR-146-5p. *PLoS One* 2016; accepted for publication: January 29, 2016.
150. Hariharan K, Hinze C, **Schmidt-Ott KM.** Assembling kidney tissues from cells: The long road from organoids to organs. *Front Cell Dev Biol* 2016; in press.
151. **Gummlich L**, Kähne T, Naumann M, Kilic E, **Jung K**, Dubiel W. New insights into the mechanism of COP9 signalosome-Cullin-RING ubiquitin-ligase pathway deregulation in urological cancers. *Int J Biochem Cell Biol* 2016; submitted: August 28, 2015.